4//SEC Filing
Delfini Lisa 4
Accession 0000950170-24-064598
CIK 0001563880other
Filed
May 23, 8:00 PM ET
Accepted
May 24, 4:12 PM ET
Size
9.1 KB
Accession
0000950170-24-064598
Insider Transaction Report
Form 4
Delfini Lisa
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-05-22$2.64/sh−4,350$11,485→ 53,279 total - Exercise/Conversion
Stock Option (right to buy)
2024-05-22−16,043→ 48,125 totalExercise: $0.51Exp: 2032-02-10→ Common Stock (16,043 underlying) - Exercise/Conversion
Common Stock
2024-05-22$0.51/sh+16,043$8,198→ 57,629 total
Footnotes (4)
- [F1]Includes 5,685 shares purchased through the Issuer's employee stock purchase plan.
- [F2]This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on May 22, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
Related Parties
1- filerCIK 0001873253
Filing Metadata
- Form type
- 4
- Filed
- May 23, 8:00 PM ET
- Accepted
- May 24, 4:12 PM ET
- Size
- 9.1 KB